Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Wearable Diagnostic for Detection of COVID-19 Infection

18 janvier 2022 mis à jour par: ClinOne, Inc.
The goals of this study are 1) to validate the use of a wearable diagnostic capability and software as a medical device (SaMD) algorithm for the pre or early-symptomatic detection of COVID-19 infection, 2) assess the wearable device on the subjects, and 3) ensure data are collected, securely stored, and easily read and interpreted by non-laboratory personnel.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

This is an open label iterative study designed to calibrate the algorithm to maximize its test characteristics. The sample size is derived from the minimum number of COVID-19 subjects required to evaluate algorithm sensitivity and specificity. A sample size of 200 true positive COVID-19 infections is anticipated to assess device predictive analytics. Assuming a six-month enrollment period, a 15 percent patient lost to follow-up rate, and a positive COVID-19 infection rate of 10 percent within the study population, a sample size of 2,352 subjects will be enrolled in this prospective study.

Primary Outcomes: The primary outcomes of interest are performance of the BioSticker multiparameter vital signs wearable and the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19 related signs and symptom in subjects prior to or coincident with a positive COVID-19 diagnostic test and the specificity of the BioSticker algorithms in distinguishing positive diagnosis of infection from negative diagnosis of infection among subjects. COVID-19 infection will be confirmed by both participant affirmation and diagnostic laboratory testing. Additional primary outcome is the intuitive presentation of affirmative diagnostic results from the BioSticker early detection algorithm(s).

Secondary Outcomes: The secondary outcomes of interest include correlation of biometric data indicators to individual-level experiential feedback reported through participant symptom-tracking and diagnostic questionnaires.

Type d'étude

Observationnel

Inscription (Réel)

790

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Colorado
      • Greenwood Village, Colorado, États-Unis, 80111
        • ClinOne, Inc

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Cohort 1- Exposed/Early Symptomatic Group All adult subjects seeking a COVID-19 test and meeting enrollment criteria will be offered enrollment into this study.

The Inclusion Criteria are:

  1. Adults - 18 years of age and older
  2. Both genders, all races and ethnic groups
  3. English speaking adult subjects only

Cohort 2- Vaccine Group:

Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine

  1. Subjects who are scheduled to receive the COVID vaccination series through local and national clinics, health systems and pharmacies.
  2. Subjects who become aware of the study through public notices, postings, and advertisements, and other marketing efforts.

La description

Cohort 1- Exposed/ Early Symptomatic Group

Inclusion Criteria:

  1. age 18 or older;
  2. able to follow the study device wear instructions per the Instructions for Use;
  3. no positive viral test within 60 days prior to enrollment; and
  4. willing and able to provide written, informed consent.

Exclusion Criteria:

  1. pregnant or breastfeeding;
  2. wearing a defibrillator or pacemaker;
  3. known or suspected cardiac dysrhythmias
  4. known or suspected allergy to adhesives;
  5. chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
  6. open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
  7. current or planned use of either an investigation pharmaceutical or an investigational device during the study.

Cohort 1- Vaccine Group

Inclusion Criteria:

Subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series are eligible for the study if they are:

  1. Age 18 or older; 12 years of age -17 years of age are approved to participate in the vaccine Cohort portion of the study.
  2. scheduled to receive their first and second dose of the Pfizer/BioNTech or Moderna COVID-19 vaccine
  3. able to follow the study device wear instructions per the Instructions for Use;
  4. no positive viral test within 60 days prior to enrollment; and
  5. willing and able to provide written, informed consent.
  6. Willing and able to take an oral temperature

Exclusion Criteria:

Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series will be excluded from the study if they are or have any of the following:

  1. pregnant or breastfeeding;
  2. wearing a defibrillator or pacemaker;
  3. known or suspected cardiac dysrhythmias
  4. known or suspected allergy to adhesives;
  5. chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
  6. open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
  7. current or planned use of either an investigation pharmaceutical or an investigational device during the study.
  8. previously fully vaccinated subjects

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Cohort 1- Exposed/Early Symptomatic

The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing.

For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day.

CoHort 2- Pfizer or Moderna Vaccine
Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series. For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.
Délai: 14 days
Biometric data will be measured for 14 days using the application of the BioSticker on the upper left side of the chest.
14 days
The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.
Délai: 14 days
Vital Signs measurements will be collected for 14 days using the application of the BioSticker on the upper left side of the chest.
14 days
The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.
Délai: 14 days
Symptom tracking data will be collected through daily questionnaires for 14 consecutive days, administered through ClinOne. Health data known to be associated with COVID-19 risk and severity, including comorbid conditions, risk factors, and demographic data will be collected from subjects during screening and enrollment via the ClinOne study website.
14 days
The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.
Délai: 14 days
BioSticker sensor data will be time-stamped and annotated against clinical events (e.g., fever, cough), symptom progression data, and other indicators of infection as they are identified. Weighting coefficients for predictive algorithms will be tuned and algorithms will be iteratively refined using machine learning methods and small batches of data anticipated to include between 20 and 50 positive cases per set, and validated against sensor data obtained from COVID-19-negative subjects.
14 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms.
Délai: 14 days
Individual-level experiential feedback will be reported through participant symptom- tracking and diagnostic questionnaires for 14 consecutive days.
14 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: James Mault, MD, BioIntelliSense, Inc

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 décembre 2020

Achèvement primaire (Réel)

15 janvier 2022

Achèvement de l'étude (Réel)

15 janvier 2022

Dates d'inscription aux études

Première soumission

14 janvier 2021

Première soumission répondant aux critères de contrôle qualité

5 février 2021

Première publication (Réel)

8 février 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 janvier 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 janvier 2022

Dernière vérification

1 janvier 2022

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur COVID-19 [feminine]

3
S'abonner